Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 66

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 66
---
 days after the Execution Date, file with the SEC an initial Registration
Statement on Form F-1 covering the maximum number of Registrable Securities as shall be permitted to be included thereon in accordance
with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor under
Rule 415 under the Securities Act at then-prevailing market prices (and not fixed prices), as mutually determined by both the Company
and the Investor in consultation with their respective legal counsel; provided, however, the Company may delay filing or suspend the use
of any Registration Statement if the Company determines upon advice of legal counsel, that in order for the registration statement to
not contain a material misstatement or omission, an amendment thereto would be needed, or if the Board of Directors, upon advice of legal
counsel, reasonably believes that such filing or use would require premature disclosure of information that could materially adversely
affect the Company; provided, however, that in the event the Investor owns Purchase Shares at the time of any such suspension of use of
the registration statement, the Company shall use reasonable best efforts to make such registration statement available for the resale
of such securities by the Investor as soon as practicable thereafter. The initial Registration Statement shall register only Registrable
Securities. The Investor and its counsel shall have a reasonable opportunity to review and comment upon such Registration Statement and
any amendment or supplement to such Registration Statement and any related prospectus prior to its filing with the SEC, and the Company
shall give due consideration to all such comments. The Investor acknowledges that it will be identified in the initial Registration Statement
(and in any New Registration Statement) as an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and the Investor
shall furnish all information reasonably requested by the Company for inclusion therein. The Company shall use its commercially reasonable
efforts to have the Registration Statement and any amendment declared effective by the SEC at the earliest practicable date. Subject to
any grace periods set forth in the Purchase Agreement, the Company shall use commercially reasonable efforts to keep the Registration
Statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investor of all of the
Registrable Securities covered thereby at all times until the earlier of (i) the date on which the Investor shall have resold all the
Registrable Securities covered by such Registration Statement and (ii) the date of termination of the Purchase Agreement if as of such